- Home
- COGT vs PHAR Comparison
COGT vs PHAR Comparison
Compare COGT & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COGT
- PHAR
- Stock Information
- Founded
- COGT 2014
- PHAR 1988
- Country
- COGT United States
- PHAR Netherlands
- Employees
- COGT N/A
- PHAR N/A
- Industry
- COGT Biotechnology: Pharmaceutical Preparations
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- COGT Health Care
- PHAR Health Care
- Exchange
- COGT Nasdaq
- PHAR Nasdaq
- Market Cap
- COGT 545.3M
- PHAR 587.5M
- IPO Year
- COGT 2018
- PHAR N/A
- Fundamental
- Price
- COGT $4.37
- PHAR N/A
- Analyst Decision
- COGT Buy
- PHAR Strong Buy
- Analyst Count
- COGT 7
- PHAR 3
- Target Price
- COGT $14.17
- PHAR $30.00
- AVG Volume (30 Days)
- COGT 1.7M
- PHAR 4.6K
- Earning Date
- COGT 05-06-2025
- PHAR 05-08-2025
- Dividend Yield
- COGT N/A
- PHAR N/A
- EPS Growth
- COGT N/A
- PHAR N/A
- EPS
- COGT N/A
- PHAR N/A
- Revenue
- COGT N/A
- PHAR $297,200,000.00
- Revenue This Year
- COGT N/A
- PHAR $8.26
- Revenue Next Year
- COGT N/A
- PHAR $9.73
- P/E Ratio
- COGT N/A
- PHAR N/A
- Revenue Growth
- COGT N/A
- PHAR 21.15
- 52 Week Low
- COGT $3.72
- PHAR $6.65
- 52 Week High
- COGT $12.61
- PHAR $11.07
- Technical
- Relative Strength Index (RSI)
- COGT 34.56
- PHAR 45.53
- Support Level
- COGT $4.12
- PHAR $7.79
- Resistance Level
- COGT $5.09
- PHAR $8.51
- Average True Range (ATR)
- COGT 0.54
- PHAR 0.47
- MACD
- COGT -0.02
- PHAR 0.01
- Stochastic Oscillator
- COGT 23.90
- PHAR 49.08
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
About PHAR Pharming Group N.V.
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.